BioCentury | Jan 7, 2021
Finance

Werewolf’s conditionally-activated cancer therapies draw $72M series B, partnering interest

...its $56 million series A are Longwood Fund, Taiho Ventures, Arkin Bio Ventures, UPMC Enterprises and DC Investment Partners...
BioCentury | Jun 18, 2020
Emerging Company Profile

Lassen emerges from Frazier with over $31M and a mAb for fibrosis and cancer

...Therapeutics’ $31 million series A round, which had participation from Alta Partners, Longwood Fund and DC Investment Partners...
...employees: 8 Funds raised: $31.5 million Investors: Frazier Healthcare Partners, Alta Partners, Longwood Fund and DC Investment Partners...
BioCentury | Nov 20, 2019
Financial News

Werewolf debuts with $56M to develop tumor-activated biologics

...Fund co-led the round with participation from Taiho Ventures, Arkin Bio Ventures, UPMC Enterprises and DC Investment Partners...
Items per page:
1 - 3 of 3
BioCentury | Jan 7, 2021
Finance

Werewolf’s conditionally-activated cancer therapies draw $72M series B, partnering interest

...its $56 million series A are Longwood Fund, Taiho Ventures, Arkin Bio Ventures, UPMC Enterprises and DC Investment Partners...
BioCentury | Jun 18, 2020
Emerging Company Profile

Lassen emerges from Frazier with over $31M and a mAb for fibrosis and cancer

...Therapeutics’ $31 million series A round, which had participation from Alta Partners, Longwood Fund and DC Investment Partners...
...employees: 8 Funds raised: $31.5 million Investors: Frazier Healthcare Partners, Alta Partners, Longwood Fund and DC Investment Partners...
BioCentury | Nov 20, 2019
Financial News

Werewolf debuts with $56M to develop tumor-activated biologics

...Fund co-led the round with participation from Taiho Ventures, Arkin Bio Ventures, UPMC Enterprises and DC Investment Partners...
Items per page:
1 - 3 of 3